GlassScriptPhysician profile
Chloe Schleicher
NPI 1104388560
$3,965.09
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $1,199 · 2023: $1,630 · 2024: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.28 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $595.73 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $345.42 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $307.19 | 2022-2023 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.73 | 2021-2024 | Jardiance, Synjardy |
| Pfizer INC. | $216.63 | 2021-2024 | |
| Dexcom, INC. | $182.25 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Axonics, INC. | $167.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $127.78 | 2022 | |
| Daiichi Sankyo INC. | $125.00 | 2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.30 | 2022-2023 | Xifaxan, Ibschek |
| Astrazeneca Pharmaceuticals LP | $107.91 | 2021-2024 | Breztri, Airsupra |
| Abbvie INC. | $83.25 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.78 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $59.57 | 2022-2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $54.31 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.01 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Vanda Pharmaceuticals INC. | $38.30 | 2021 | |
| Eisai INC. | $37.28 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $35.71 | 2022-2023 | Keveyis |
| Esperion Therapeutics, INC. | $31.14 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $29.94 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $18.74 | 2024 | |
| Boston Scientific Corporation | $16.24 | 2024 | Watchman Flx |
| Shield Therapeutics INC | $16.12 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $15.81 | 2022 | |
| Lucid Diagnostics INC. | $14.88 | 2023 | |
| Vistapharm, INC. | $14.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Schleicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.